Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:25:12 EST Wed 17 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:ABCL - ABCELLERA BIOLOGICS INC - https://www.abcellera.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ABCL - Q0.13.41·3.500.73.46-0.05-1.42,380.67,8797,2713.475  3.57  3.416.515  1.890619:42:06Dec 0815 min RT 2¢

Recent Trades - Last 10 of 7271
Time ETExPriceChangeVolume
19:42:06Q3.44-0.0723
19:33:02Q3.44-0.07100
19:33:02Q3.44-0.0797
19:32:12Q3.4988-0.011299
19:26:51Q3.4994-0.01061,000
19:20:26Q3.50-0.012
19:00:07Q3.4513-0.058734
18:58:11Q3.50-0.0150
18:58:03Q3.45-0.063
18:58:03Q3.46-0.051

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-08 16:05U:ABCLNews ReleaseAbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
2025-11-10 09:00U:ABCLNews ReleaseAbCellera Appoints Dr. Stephen Quake to its Board of Directors
2025-11-06 16:05U:ABCLNews ReleaseAbCellera Reports Q3 2025 Business Results
2025-10-07 16:05U:ABCLNews ReleaseAbCellera to Participate at Upcoming Investor Conferences in November and December 2025
2025-09-29 16:05U:ABCLNews ReleaseAbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
2025-09-10 09:07U:ABCLNews ReleaseAbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
2025-08-27 09:00U:ABCLNews ReleaseAbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
2025-08-12 16:05U:ABCLNews ReleaseAbCellera to Participate at Upcoming Investor Conferences in September
2025-08-07 16:05U:ABCLNews ReleaseAbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
2025-07-07 16:05U:ABCLNews ReleaseAbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
2025-05-30 13:00U:ABCLNews ReleaseAbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
2025-05-14 17:00U:ABCLNews ReleaseAbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
2025-05-12 15:30U:ABCLNews ReleaseAbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
2025-05-09 19:30U:ABCLNews ReleaseAbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
2025-05-08 16:05U:ABCLNews ReleaseAbCellera Reports Q1 2025 Business Results
2025-04-29 15:00U:ABCLNews ReleaseAbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025
2025-04-08 16:05U:ABCLNews ReleaseAbCellera to Participate at Upcoming Investor Conferences in May and June
2025-04-03 16:05U:ABCLNews ReleaseAbCellera to Report First Quarter 2025 Financial Results on May 8, 2025
2025-03-25 16:30U:ABCLNews ReleaseAbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
2025-02-27 16:05U:ABCLNews ReleaseAbCellera Reports Full Year 2024 Business Results